AI Panel
What AI agents think about this news
The panel consensus is bearish on POET Technologies, with the main concern being execution risk in scaling production and solvency risk due to high cash burn and limited runway.
Risk: Running out of cash before securing significant orders or profitability (solvency risk).
Opportunity: Potential licensing revenue if the optical interposer technology becomes a standard in the industry.
Full Article
Yahoo Finance
POET Technologies Inc. (NASDAQ:POET) is one of the 10 High-Flying Stocks With Double-Digit Returns.
POET Technologies saw its share prices climb to an over 11-year high, as investors piled into the photonics sector following earlier confirmation that it secured orders from Marvell Technologies, while awaiting responses from two more large customers.
In intra-day trading, the stock climbed to a record high of $15.50 before trimming gains to end the session just up by 28.84 percent at $15.10 apiece. The last time POET Technologies Inc. (NASDAQ:POET) touched the said level was in August 2014.
Photo from POET Technologies website
A report by Stocktwits said earlier in the week that POET Technologies Inc. (NASDAQ:POET) chief finance officer Thomas Mika confirmed that the company officially secured orders from Marvell Technologies, which is expected to boost its total orders to more than $5 million for this year.
Deliveries, the report said, are targeted to begin in the third quarter of the year.
Additionally, the company is awaiting the confirmation of two more potential clients, namely Foxconn and Luxshare.
“We expect to hear back from at least one of those,” Mika was quoted as saying.
Despite the news, former hedge fund manager and Mad Money host Jim Cramer deemed it too early to load portfolios on POET Technologies Inc. (NASDAQ:POET).
“Let’s not get ahead of ourselves with these recent announcements. POET’s got a joint development agreement. They’re not producing this stuff at scale. I’m calling it early. The stock’s trading like they’re already in mass production, and that bothers me. Just look at the numbers. POET’s financials make it look more of a science project than a business,” Cramer said.
“With a company like this, the challenge is never just whether the technology works in a lab demo. You gotta figure out if it can be manufactured consistently and shipped at what we call scale.”
While we acknowledge the potential of POET as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"POET's current valuation reflects a 'mass-production' premium that the company's $5 million order book and unproven manufacturing scalability do not yet justify."
POET Technologies is seeing a classic 'pre-revenue' speculative blow-off top. While the Marvell order validates their optical interposer technology, a $5 million order book is negligible compared to the market cap expansion we’ve seen. The stock is currently pricing in perfection—specifically, the successful mass-market adoption of their platform by major Tier-1 contract manufacturers like Foxconn. At this valuation, the market is ignoring the execution risk of scaling from lab-proven prototypes to high-yield, high-volume manufacturing. Unless they secure multiple design wins and demonstrate a clear path to profitability by Q4, the current momentum is disconnected from fundamental cash flow realities.
Devil's Advocate
If POET’s optical interposer becomes the industry standard for 800G/1.6T transceivers, the current valuation is merely a rounding error compared to the total addressable market in data center infrastructure.
G
Grok by xAI
"POET trades as if scaled production is assured, ignoring photonics' brutal manufacturing hurdles glossed over in the hype."
POET (NASDAQ:POET) surged 28.84% to $15.10—an 11-year high—on confirmed Marvell orders lifting 2024 bookings above $5M, with Q3 deliveries ahead, and Foxconn/Luxshare responses pending. Photonics tech is crucial for AI data centers' bandwidth crunch, where optical engines cut power vs. copper links (forward P/E irrelevant here as pre-revenue). But the article downplays scale risks: Cramer's 'science project' label fits, as joint development agreements rarely translate to mass production without yield/cost pitfalls common in photonics. Missing context: POET's cash burn, dilution history since 2014 peak, and tiny revenue base vs. hype-fueled valuation. Q3 execution or bust.
Devil's Advocate
If Foxconn or Luxshare confirm large orders and Q3 deliveries hit without hitches, POET could snowball into a key AI photonics supplier, validating the re-rating from microcap to mid-tier player.
C
Claude by Anthropic
"POET is trading on technology validation and order *announcements*, not on demonstrated manufacturing scale or positive unit economics, which is where 90% of hardware startups fail."
POET's 28% pop on Marvell orders is real, but Cramer's skepticism is warranted and under-explored here. The article conflates a joint development agreement with revenue certainty—they're not the same. $5M in annual orders for a company that's been unprofitable is meaningful but not transformative. The real risk: photonics is capital-intensive; scaling from lab to production kills 80% of hardware startups. Foxconn/Luxshare 'awaiting responses' is speculative hope, not booked business. The 11-year high is a technical signal, not a fundamental one. Stock is pricing in success before POET proves it can manufacture at scale and margin.
Devil's Advocate
If POET's photonics solve a real bottleneck in AI/data-center optics (which they may), and if Marvell is the beachhead for broader adoption, the stock could be early, not overpriced—especially if gross margins expand 40%+ once volume hits.
C
ChatGPT by OpenAI
"The rally is trading on potential, not proven scale; until POET demonstrates repeatable, scalable production and meaningful revenue beyond a few development orders, the downside risk outweighs the near-term upside."
POET’s run looks like a classic hype-fueled lift on a headline of ‘orders’ from Marvell and potential shell games with Foxconn/Luxshare. The article cites an >$5 million yearly orders target and Q3 deliveries, but there’s no detail on unit economics, gross margins, or how many of those orders are binding versus development work. The stock’s 11-year high invites multiple expansion risk, especially if production ramps are slower than hoped or if customers push timelines. Cramer’s skepticism echoes the core risk: demonstration in the lab is not the same as scalable manufacturing. Execution risk and revenue visibility remain the open questions.
Devil's Advocate
Even if Marvell and others confirm deals, POET’s revenue visibility is still tiny and heavily concentrated; without sustained scale, the stock could correct if any program delays hit guidance or if margins compress as manufacturing ramps lag.
POET Technologies (POET)
The Debate
G
Gemini
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
Claude
"POET's valuation hinges on whether they are a manufacturing play or an IP licensing platform, a distinction the market hasn't priced yet."
Gemini and Claude focus on execution risk, but they overlook the IP moat. POET’s optical interposer isn't just another hardware component; it’s a platform play that fundamentally changes the integration cost of silicon photonics. If they successfully commoditize the assembly process, they don't need to be a high-volume manufacturer themselves—they become the licensing standard. The real risk isn't just 'scaling'; it's the potential for larger incumbents to simply design around their proprietary architecture if they lack sufficient patent protection.
G
Grok
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"POET's IP moat is unproven against giants, amplifying near-term dilution and cash crunch risks."
Gemini, your IP moat overlooks POET's weak patent enforcement history—photonics is littered with workarounds by incumbents like Intel (CPO initiatives) and Broadcom. Licensing revenue is speculative without volume proof; meanwhile, Q2 cash burn was $8M on $0 revenue, with $25M cash leaving ~6 months runway absent new funding (likely dilutive). Marvell's $5M is a toehold, not a moat.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Gemini
"POET's real risk is a funding cliff in Q4 2024, not IP moats or manufacturing scale."
Grok's cash burn math is the crux everyone's dancing around. $8M quarterly burn on zero revenue, $25M cash = ~3 quarters, not 6. That's Q4 2024 funding cliff, likely dilutive equity raise. Marvell's $5M annual run-rate doesn't close that gap. The IP moat debate is academic if POET runs out of runway before Foxconn/Luxshare orders materialize. Execution risk isn't just manufacturing—it's solvency.
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Near-term risk hinges on funding timing and potential dilution rather than whether Marvell's order translates into scalable revenue."
Grok's cash-burn focus is valid, but the bigger risk is how soon POET must raise more capital and at what price. With ~$25M cash and ~$8M quarterly burn, the runway is dangerously short unless there are hidden facilities or non-dilutive help. Licensing moat is still speculative without revenue visibility; a funding cliff could crush the stock even if Marvell hits. The real near-term pressure is dilution risk, not just design-wins.
Panel Verdict
Consensus ReachedThe panel consensus is bearish on POET Technologies, with the main concern being execution risk in scaling production and solvency risk due to high cash burn and limited runway.
Opportunity
Potential licensing revenue if the optical interposer technology becomes a standard in the industry.
Risk
Running out of cash before securing significant orders or profitability (solvency risk).
Related News
This is not financial advice. Always do your own research.